Pernar CH, Ebot EM, Wilson KM and Mucci LA: The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 8(pii): a0303612018. View Article : Google Scholar : PubMed/NCBI

Mitsuzuka K and Arai Y: Metabolic changes in patients with prostate cancer during androgen deprivation therapy. Int J Urol. 25:45–53. 2018. View Article : Google Scholar : PubMed/NCBI

Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, et al: The mutational landscape of lethal castration-resistant prostate cancer. Nature. 487:239–243. 2012. View Article : Google Scholar : PubMed/NCBI

Sung B, Prasad S, Yadav VR, Lavasanifar A and Aggarwal BB: Cancer and diet: How are they related? Free Radic Res. 45:864–879. 2011. View Article : Google Scholar : PubMed/NCBI

Zhang HY, Cui J, Zhang Y, Wang ZL, Chong T and Wang ZM: Isoflavones and prostate cancer: A review of some critical issues. Chin Med J (Engl). 129:341–347. 2016. View Article : Google Scholar : PubMed/NCBI

Patel RP, Boersma BJ, Crawford JH, Hogg N, Kirk M, Kalyanaraman B, Parks DA, Barnes S and Darley-Usmar V: Antioxidant mechanisms of isoflavones in lipid systems: Paradoxical effects of peroxyl radical scavenging. Free Radic Biol Med. 31:1570–1581. 2001. View Article : Google Scholar : PubMed/NCBI

Yen GC and Lai HH: Inhibition of reactive nitrogen species effects in vitro and in vivo by isoflavones and soy-based food extracts. J Agric Food Chem. 51:7892–7900. 2003. View Article : Google Scholar : PubMed/NCBI

Braakhuis AJ, Campion P and Bishop KS: Reducing breast cancer recurrence: The role of dietary polyphenolics. Nutrients. 8(pii): E5472016. View Article : Google Scholar : PubMed/NCBI

Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S and Gustafsson JA: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 138:863–870. 1997. View Article : Google Scholar : PubMed/NCBI

Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M and Fukami Y: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem. 262:5592–5595. 1987.PubMed/NCBI

Rabiau N, Kossaï M, Braud M, Chalabi N, Satih S, Bignon YJ and Bernard-Gallon DJ: Genistein and daidzein act on a panel of genes implicated in cell cycle and angiogenesis by polymerase chain reaction arrays in human prostate cancer cell lines. Cancer Epidemiol. 34:200–206. 2010. View Article : Google Scholar : PubMed/NCBI

Bektic J, Berger AP, Pfeil K, Dobler G, Bartsch G and Klocker H: Androgen receptor regulation by physiological concentrations of the isoflavonoid genistein in androgen-dependent LNCaP cells is mediated by estrogen receptor beta. Eur Urol. 45:245–251. 2004. View Article : Google Scholar : PubMed/NCBI

Fritz WA, Wang J, Eltoum IE and Lamartiniere CA: Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. Mol Cell Endocrinol. 186:89–99. 2002. View Article : Google Scholar : PubMed/NCBI

Mahmoud AM, Yang W and Bosland MC: Soy isoflavones and prostate cancer: A review of molecular mechanisms. J Steroid Biochem Mol Biol. 140:161–132. 2014. View Article : Google Scholar

Applegate CC, Rowles JL, Ranard KM, Jeon S and Erdman JW: Soy consumption and the risk of prostate cancer: An updated systematic review and meta-analysis. Nutrients. 10(pii): E402018. View Article : Google Scholar : PubMed/NCBI

Kumar R: Steroid hormone receptors and prostate cancer: Role of structural dynamics in therapeutic targeting. Asian J Androl. 18:682–686. 2016. View Article : Google Scholar : PubMed/NCBI

Jenster G, van der Korput HA, Trapman J and Brinkmann AO: Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem. 270:7341–7346. 1995. View Article : Google Scholar : PubMed/NCBI

Kumar R and McEwan IJ: Allosteric modulators of steroid hormone receptors: Structural dynamics and gene regulation. Endocr Rev. 33:271–299. 2012. View Article : Google Scholar : PubMed/NCBI

Monaghan AE and McEwan IJ: A sting in the tail: The N-terminal domain of the androgen receptor as a drug target. Asian J Androl. 18:687–694. 2016. View Article : Google Scholar : PubMed/NCBI

Lavery DN and McEwan IJ: Functional characterization of the native NH2-terminal transactivation domain of the human androgen receptor: Binding kinetics for interactions with TFIIF and SRC-1a. Biochemistry. 47:3352–3359. 2008. View Article : Google Scholar : PubMed/NCBI

Verrijdt G, Tanner T, Moehren U, Callewaert L, Haelens A and Claessens F: The androgen receptor DNA-binding domain determines androgen selectivity of transcriptional response. Biochem Soc Trans. 34:1089–1094. 2006. View Article : Google Scholar : PubMed/NCBI

Zhou ZX, Wong CI, Sar M and Wilson EM: The androgen receptor: An overview. Recent Prog Horm Res. 49:249–274. 1994.PubMed/NCBI

Matias PM, Donner P, Coelho R, Thomaz M, Peixoto C, Macedo S, Otto N, Joschko S, Scholz P, Wegg A, et al: Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. J Biol Chem. 275:26164–26171. 2000. View Article : Google Scholar : PubMed/NCBI

Davey RA and Grossmann M: Androgen receptor structure, function and biology: From bench to bedside. Clin Biochem Rev. 37:3–15. 2016.PubMed/NCBI

Veldscholte J, Berrevoets CA, Zegers ND, van der Kwast TH, Grootegoed JA and Mulder E: Hormone-induced dissociation of the androgen receptor-heat-shock protein complex: Use of a new monoclonal antibody to distinguish transformed from nontransformed receptors. Biochemistry. 31:7422–7430. 1992. View Article : Google Scholar : PubMed/NCBI

van der Steen T, Tindall DJ and Huang H: Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci. 14:14833–14859. 2013. View Article : Google Scholar : PubMed/NCBI

Boam T: Anti-androgenic effects of flavonols in prostate cancer. Ecancermedicalscience. 9:5852015.PubMed/NCBI

D'Archivio M, Filesi C, Di Benedetto R, Gargiulo R, Giovannini C and Masella R: Polyphenols, dietary sources and bioavailability. Ann Ist Super Sanita. 43:348–361. 2007.PubMed/NCBI

Trebatická J and Ďuračková Z: Psychiatric disorders and polyphenols: Can they be helpful in therapy? Oxid Med Cell Longev 2015. 2485292015.

Crozier A, Jaganath IB and Clifford MN: Phenols, polyphenols and tannins: An overview, in plant secondary metabolites: Occurrence, structure and role in the human diet. Crozier A, Clifford MN and Ashihara H: Oxford: Blackwell Publishing Ltd; pp. 1–24. 2006

Cassidy A and Minihane AM: The role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids. Am J Clin Nutr. 105:10–22. 2017. View Article : Google Scholar : PubMed/NCBI

Adegbola P, Aderibigbe I, Hammed W and Omotayo T: Antioxidant and anti-inflammatory medicinal plants have potential role in the treatment of cardiovascular disease: A review. Am J Cardiovasc Dis. 7:19–32. 2017.PubMed/NCBI

Barbieri R, Coppo E, Marchese A, Daglia M, Sobarzo-Sánchez E, Nabavi SF and Nabavi SM: Phytochemicals for human disease: An update on plant-derived compounds antibacterial activity. Microbiol Res. 196:44–68. 2017. View Article : Google Scholar : PubMed/NCBI

Crozier A, Jaganath IB and Clifford MN: Dietary phenolics: Chemistry, bioavailability and effects on health. Nat Prod Rep. 26:1001–1043. 2009. View Article : Google Scholar : PubMed/NCBI

Costa SL, Silva VD, Dos Santos Souza C, Santos CC, Paris I, Muñoz P and Segura-Aguilar J: Impact of plant-derived flavonoids on neurodegenerative diseases. Neurotox Res. 30:41–52. 2016. View Article : Google Scholar : PubMed/NCBI

Wang J, Tang L and Wang JS: Biomarkers of dietary polyphenols in cancer studies: Current evidence and beyond. Oxid Med Cell Longev. 2015:7323022015. View Article : Google Scholar : PubMed/NCBI

Hilakivi-Clarke L, Andrade JE and Helferich W: Is soy consumption good or bad for the breast? J Nutr. 140:2326S–2334S. 2010. View Article : Google Scholar : PubMed/NCBI

Setchell KD, Brown NM, Desai PB, Zimmer-Nechimias L, Wolfe B, Jakate AS, Creutzinger V and Heubi JE: Bioavailability, disposition, and dose-response effects of soy isoflavones when consumed by healthy women at physiologically typical dietary intakes. J Nutr. 133:1027–1035. 2003. View Article : Google Scholar : PubMed/NCBI

Mondot S and Lepage P: The human gut microbiome and its dysfunctions through the meta-omics prism. Ann N Y Acad Sci. 1372:9–19. 2016. View Article : Google Scholar : PubMed/NCBI

Landete JM, Arqués J, Medina M, Gaya P, de Las Rivas B and Muñoz R: Bioactivation of phytoestrogens: Intestinal bacteria and health. Crit Rev Food Sci Nutr. 56:1826–1843. 2016. View Article : Google Scholar : PubMed/NCBI

Rafii F: The role of colonic bacteria in the metabolism of the natural isoflavone daidzin to equol. Metabolites. 5:56–73. 2015. View Article : Google Scholar : PubMed/NCBI

Heinonen SM, Hoikkala A, Wähälä K and Adlercreutz H: Metabolism of the soy isoflavones daidzein, genistein and glycitein in human subjects. Identification of new metabolites having an intact isoflavonoid skeleton. J Steroid Biochem Mol Biol. 87:285–299. 2003. View Article : Google Scholar : PubMed/NCBI

Pilšáková L, Riečanský I and Jagla F: The physiological actions of isoflavone phytoestrogens. Physiol Res. 59:651–664. 2010.PubMed/NCBI

Manach C, Williamson G, Morand C, Scalbert A and Rémésy C: Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr. 81 Suppl 1:230S–242S. 2005. View Article : Google Scholar : PubMed/NCBI

Barnes S: The biochemistry, chemistry and physiology of the isoflavones in soybeans and their food products. Lymphat Res Biol. 8:89–98. 2010. View Article : Google Scholar : PubMed/NCBI

Murphy PA, Barua K and Hauck CC: Solvent extraction selection in the determination of isoflavones in soy foods. J Chromatogr B. 777:129–138. 2002. View Article : Google Scholar

Bai W, Wang C and Ren C: Intakes of total and individual flavonoids by US adults. Int J Food Sci Nutr. 65:9–20. 2014. View Article : Google Scholar : PubMed/NCBI

Van E, rp-Baart MA, Brants HA, Kiely M, Mulligan A, Turrini A, Sermoneta C, Kilkkinen A and Valsta LM: Isoflavone intake in four different European countries: The VENUS approach. Br J Nutr. 89 Suppl 1:S25–S30. 2003.PubMed/NCBI

Sureda A, Sanches Silva A, Sánchez-Machado DI, López-Cervantes J, Daglia M, Nabavi SF and Nabavi SM: Hypotensive effects of genistein: From chemistry to medicine. Chem Biol Interact. 268:37–46. 2017. View Article : Google Scholar : PubMed/NCBI

Rahman Mazumder MA and Hongsprabhas P: Genistein as antioxidant and antibrowning agents in in vivo and in vitro: A review. Biomed Pharmacother. 82:379–392. 2016. View Article : Google Scholar : PubMed/NCBI

Messina MJ, Persky V, Setchell KD and Barnes S: Soy intake and cancer risk: A review of the in vitro and in vivo data. Nutr Cancer. 21:113–131. 1994. View Article : Google Scholar : PubMed/NCBI

Baxa DM, Luo X and Yoshimura FK: Genistein induces apoptosis in T lymphoma cells via mitochondrial damage. Nutr Cancer. 51:93–101. 2005. View Article : Google Scholar : PubMed/NCBI

Baxa DM and Yoshimura FK: Genistein reduces NF-kappa B in T lymphoma cells via a caspase-mediated cleavage of I kappa B alpha. Biochem Pharmacol. 66:1009–1018. 2003. View Article : Google Scholar : PubMed/NCBI

Seo YJ, Kim BS, Chun SY, Park YK, Kang KS and Kwon TG: Apoptotic effects of genistein, biochanin-A and apigenin on LNCaP and PC-3 cells by p21 through transcriptional inhibition of polo-like kinase-1. J Korean Med Sci. 26:1489–1494. 2011. View Article : Google Scholar : PubMed/NCBI

Shen JC, Klein RD, Wei Q, Guan Y, Contois JH, Wang TT, Chang S and Hursting SD: Low-dose genistein induces cyclin-dependent kinase inhibitors and G(1) cell-cycle arrest in human prostate cancer cells. Mol Carcinog. 29:92–102. 2000. View Article : Google Scholar : PubMed/NCBI

Majid S, Kikuno N, Nelles J, Noonan E, Tanaka Y, Kawamoto K, Hirata H, Li LC, Zhao H, Okino ST, et al: Genistein induces the p21WAF1/CIP1 and p16INK4a tumor suppressor genes in prostate cancer cells by epigenetic mechanisms involving active chromatin modification. Cancer Res. 68:2736–2744. 2008. View Article : Google Scholar : PubMed/NCBI

Agarwal R: Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol. 60:1051–1059. 2000. View Article : Google Scholar : PubMed/NCBI

Wang BF, Wang JS, Lu JF, Kao TH and Chen BH: Antiproliferation effect and mechanism of prostate cancer cell lines as affected by isoflavones from soybean cake. J Agric Food Chem. 57:2221–2232. 2009. View Article : Google Scholar : PubMed/NCBI

Li W, Frame LT, Hoo KA, Li Y, D'Cunha N and Cobos E: Genistein inhibited proliferation and induced apoptosis in acute lymphoblastic leukemia, lymphoma and multiple myeloma cells in vitro. Leuk Lymphoma. 52:2380–2390. 2011. View Article : Google Scholar : PubMed/NCBI

Guo Y, Wang S, Hoot DR and Clinton SK: Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones. J Nutr Biochem. 18:408–417. 2007. View Article : Google Scholar : PubMed/NCBI

Li Y, Che M, Bhagat S, Ellis KL, Kucuk O, Doerge DR, Abrams J, Cher ML and Sarkar FH: Regulation of gene expression and inhibition of experimental prostate cancer bone metastasis by dietary genistein. Neoplasia. 6:354–363. 2004. View Article : Google Scholar : PubMed/NCBI

Li Y and Sarkar FH: Down-regulation of invasion and angiogenesis-related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. Cancer Lett. 186:157–164. 2002. View Article : Google Scholar : PubMed/NCBI

Sargeant P, Farndale RW and Sage SO: The tyrosine kinase inhibitors methyl 2,5-dihydroxycinnamate and genistein reduce thrombin-evoked tyrosine phosphorylation and Ca2+ entry in human platelets. FEBS Lett. 315:242–246. 1993. View Article : Google Scholar : PubMed/NCBI

Sathyamoorthy N and Wang TT: Differential effects of dietary phyto-oestrogens daidzein and equol on human breast cancer MCF-7 cells. Eur J Cancer. 33:2384–2389. 1997. View Article : Google Scholar : PubMed/NCBI

Gętek M, Czech N, Muc-Wierzgoń M, Grochowska-Niedworok E, Kokot T and Nowakowska-Zajdel E: The active role of leguminous plant components in type 2 diabetes. Evid Based Complement Alternat Med. 2014:2939612014. View Article : Google Scholar : PubMed/NCBI

Mitchell JH, Gardner PT, McPhail DB, Morrice PC, Collins AR and Duthie GG: Antioxidant efficacy of phytoestrogens in chemical and biological model systems. Arch Biochem Biophys. 360:142–148. 1998. View Article : Google Scholar : PubMed/NCBI

Kang KA, Zhang R, Piao MJ, Lee KH, Kim BJ, Kim SY, Kim HS, Kim DH, You HJ and Hyun JW: Inhibitory effects of glycitein on hydrogen peroxide induced cell damage by scavenging reactive oxygen species and inhibiting c-Jun N-terminal kinase. Free Radic Res. 41:720–729. 2007. View Article : Google Scholar : PubMed/NCBI

Ziaei S and Halaby R: Dietary isoflavones and breast cancer risk. Medicines (Basel). 4(pii): E182017. View Article : Google Scholar : PubMed/NCBI

Vitale DC, Piazza C, Melilli B, Drago F and Salomone S: Isoflavones: Estrogenic activity, biological effect and bioavailability. Eur J Drug Metab Pharmacokinet. 38:15–25. 2013. View Article : Google Scholar : PubMed/NCBI

Couse JF, Lindzey J, Grandien K, Gustafsson JA and Korach KS: Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalpha-knockout mouse. Endocrinology. 138:4613–4621. 1997. View Article : Google Scholar : PubMed/NCBI

Lee JY, Kim HS and Song YS: Genistein as a potential anticancer agent against ovarian cancer. J Tradit Complement Med. 2:96–104. 2012. View Article : Google Scholar : PubMed/NCBI

Mahmoud AM, Al-Alem U, Ali MM and Bosland MC: Genistein increases estrogen receptor beta expression in prostate cancer via reducing its promoter methylation. J Steroid Biochem Mol Biol. 152:62–75. 2015. View Article : Google Scholar : PubMed/NCBI

Fixemer T, Remberger K and Bonkhoff H: Differential expression of the estrogen receptor beta (ERbeta) in human prostate tissue, premalignant changes, and in primary, metastatic, and recurrent prostatic adenocarcinoma. Prostate. 54:79–87. 2003. View Article : Google Scholar : PubMed/NCBI

Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B and Gustafsson JA: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology. 139:4252–4263. 1998. View Article : Google Scholar : PubMed/NCBI

Banerjee S, Li Y, Wang Z and Sarkar FH: Multi-targeted therapy of cancer by genistein. Cancer Lett. 269:226–242. 2008. View Article : Google Scholar : PubMed/NCBI

An J, Tzagarakis-Foster C, Scharschmidt TC, Lomri N and Leitman DC: Estrogen receptor beta-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J Biol Chem. 276:17808–17814. 2001. View Article : Google Scholar : PubMed/NCBI

Muthyala RS, Ju YH, Sheng S, Williams LD, Doerge DR, Katzenellenbogen BS, Helferich WG and Katzenellenbogen JA: Equol, a natural estrogenic metabolite from soy isoflavones: Convenient preparation and resolution of R- and S-equols and their differing binding and biological activity through estrogen receptors alpha and beta. Bioorg Med Chem. 12:1559–1567. 2004. View Article : Google Scholar : PubMed/NCBI

Setchell KD, Clerici C, Lephart ED, Cole SJ, Heenan C, Castellani D, Wolfe BE, Nechemias-Zimmer L, Brown NM, Lund TD, et al: S-equol, a potent ligand for estrogen receptor beta, is the exclusive enantiomeric form of the soy isoflavone metabolite produced by human intestinal bacterial flora. Am J Clin Nutr. 81:1072–1079. 2005. View Article : Google Scholar : PubMed/NCBI

Song TT, Hendrich S and Murphy PA: Estrogenic activity of glycitein, a soy isoflavone. J Agric Food Chem. 47:1607–1610. 1999. View Article : Google Scholar : PubMed/NCBI

Wang H, Li J, Gao Y, Xu Y, Pan Y, Tsuji I, Sun ZJ and Li XM: Xeno-oestrogens and phyto-oestrogens are alternative ligands for the androgen receptor. Asian JAndrol. 12:535–547. 2010. View Article : Google Scholar

Lund TD, Munson DJ, Haldy ME, Setchell KD, Lephart ED and Handa RJ: Equol is a novel anti-androgen that inhibits prostate growth and hormone feedback. Biol Reprod. 70:1188–1195. 2004. View Article : Google Scholar : PubMed/NCBI

Itsumi M, Shiota M, Takeuchi A, Kashiwagi E, Inokuchi J, Tatsugami K, Kajioka S, Uchiumi T, Naito S, Eto M and Yokomizo A: Equol inhibits prostate cancer growth through degradation of androgen receptor by S-phase kinase-associated protein 2. Cancer Sci. 107:1022–1028. 2016. View Article : Google Scholar : PubMed/NCBI

Pratt WB and Toft DO: Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev. 18:306–360. 1997. View Article : Google Scholar : PubMed/NCBI

Basak S, Pookot D, Noonan EJ and Dahiya R: Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function. Mol Cancer Ther. 7:3195–3202. 2008. View Article : Google Scholar : PubMed/NCBI

Chen L, Meng S, Wang H, Bali P, Bai W, Li B, Atadja P, Bhalla KN and Wu J: Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther. 4:1311–1319. 2005. View Article : Google Scholar : PubMed/NCBI

Li Y, Wang Z, Kong D, Li R, Sarkar SH and Sarkar FH: Regulation of Akt/FOXO3a/GSK-3beta/AR signaling network by isoflavone in prostate cancer cells. J Biol Chem. 283:27707–27716. 2008. View Article : Google Scholar : PubMed/NCBI

Lazarevic B, Karlsen SJ and Saatcioglu F: Genistein differentially modulates androgen-responsive gene expression and activates JNK in LNCaP cells. Oncol Rep. 19:1231–1235. 2008.PubMed/NCBI

Maggiolini M, Vivacqua A, Carpino A, Bonofiglio D, Fasanella G, Salerno M, Picard D and Andó S: The mutant androgen receptor T877A mediates the proliferative but not the cytotoxic dose-dependent effects of genistein and quercetin on human LNCaP prostate cancer cells. Mol Pharmacol. 62:1027–1035. 2002. View Article : Google Scholar : PubMed/NCBI

Gao S, Liu GZ and Wang Z: Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate. 59:214–225. 2004. View Article : Google Scholar : PubMed/NCBI

Mahmoud AM, Zhu T, Parray A, Siddique HR, Yang W, Saleem M and Bosland MC: Differential effects of genistein on prostate cancer cells depend on mutational status of the androgen receptor. PLoS One. 8:e784792013. View Article : Google Scholar : PubMed/NCBI

Veldscholte J, Ris-Stalpers C, Kuiper GG, Jenster G, Berrevoets C, Claassen E, van Rooij HC, Trapman J, Brinkmann AO and Mulder E: A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun. 173:534–540. 1990. View Article : Google Scholar : PubMed/NCBI

Weng C, Cai J, Wen J, Yuan H, Yang K, Imperato-McGinley J and Zhu YS: Differential effects of estrogen receptor ligands on regulation of dihydrotestosterone-induced cell proliferation in endothelial and prostate cancer cells. Int J Oncol. 42:327–337. 2013. View Article : Google Scholar : PubMed/NCBI

Takahashi Y, Hursting SD, Perkins SN, Wang TC and Wang TT: Genistein affects androgen-responsive genes through both androgen- and estrogen-induced signaling pathways. Mol Carcinog. 45:18–25. 2006. View Article : Google Scholar : PubMed/NCBI

Wang J, Eltoum IE and Lamartiniere CA: Genistein alters growth factor signalling in transgenic prostate model (TRAMP). Mol Cell Endocrinol. 219:171–180. 2004. View Article : Google Scholar : PubMed/NCBI

Lateef A, Khan AQ, Tahir M, Khan R, Rehman MU, Ali F, Hamiza OO and Sultana S: Androgen deprivation by flutamide modulates uPAR, MMP-9 expressions, lipid profile, and oxidative stress: Amelioration by daidzein. Mol Cell Biochem. 374:49–59. 2013. View Article : Google Scholar : PubMed/NCBI

Loutchanwoot P, Srivilai P and Jarry H: Lack of anti-androgenic effects of equol on reproductive neuroendocrine function in the adult male rat. Horm Behav. 65:22–31. 2014. View Article : Google Scholar : PubMed/NCBI

Legg RL, Tolman JR, Lovinger CT, Lephart ED, Setchell KD and Christensen MJ: Diets high in selenium and isoflavones decrease androgen-regulated gene expression in healthy rat dorsolateral prostate. Reprod Biol Endocrinol. 6:572008. View Article : Google Scholar : PubMed/NCBI

Onozawa M, Fukuda K, Ohtani M, Akaza H, Sugimura T and Wakabayashi K: Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cancer cell line LNCaP. Jpn J Clin Oncol. 28:360–363. 1998. View Article : Google Scholar : PubMed/NCBI

Davis JN, Muqim N, Bhuiyan M, Kucuk O, Pienta KJ and Sarkar FH: Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. Int J Oncol. 16:1091–1097. 2000.PubMed/NCBI

Peternac D, Klima I, Cecchini MG, Schwaninger R, Studer UE and Thalmann GN: Agents used for chemoprevention of prostate cancer may influence PSA secretion independently of cell growth in the LNCaP model of human prostate cancer progression. Prostate. 68:1307–1318. 2008. View Article : Google Scholar : PubMed/NCBI

Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D, Fontana J, Chinni S, Davis J, Forman J, et al: Soy isoflavones in the treatment of prostate cancer. Nutr Cancer. 47:111–117. 2003. View Article : Google Scholar : PubMed/NCBI

Kumar NB, Cantor A, Allen K, Riccardi D, Besterman-Dahan K, Seigne J, Helal M, Salup R and Pow-Sang J: The specific role of isoflavones in reducing prostate cancer risk. Prostate. 59:141–147. 2004. View Article : Google Scholar : PubMed/NCBI

Dalais FS, Meliala A, Wattanapenpaiboon N, Frydenberg M, Suter DA, Thomson WK and Wahlqvist ML: Effects of a diet rich in phytoestrogens on prostate-specific antigen and sex hormones in men diagnosed with prostate cancer. Urology. 64:510–515. 2004. View Article : Google Scholar : PubMed/NCBI

Schröder FH, Roobol MJ, Boevé ER, de Mutsert R, Zuijdgeest-van Leeuwen SD, Kersten I, Wildhagen MF and van Helvoort A: Randomized, double-blind, placebo-controlled crossover study in men with prostate cancer and rising PSA: Effectiveness of a dietary supplement. Eur Urol. 48:922–931. 2005. View Article : Google Scholar : PubMed/NCBI

Kranse R, Dagnelie PC, van Kemenade MC, de Jong FH, Blom JH, Tijburg LB, Weststrate JA and Schröder FH: Dietary intervention in prostate cancer patients: PSA response in a randomized double-blind placebo-controlled study. Int J Cancer. 113:835–840. 2005. View Article : Google Scholar : PubMed/NCBI

Vaishampayan U, Hussain M, Banerjee M, Seren S, Sarkar FH, Fontana J, Forman JD, Cher ML, Powell I, Pontes JE and Kucuk O: Lycopene and soy isoflavones in the treatment of prostate cancer. Nutr Cancer. 59:1–7. 2007. View Article : Google Scholar : PubMed/NCBI

Grainger EM, Schwartz SJ, Wang S, Unlu NZ, Boileau TW, Ferketich AK, Monk JP, Gong MC, Bahnson RR, DeGroff VL and Clinton SK: A combination of tomato and soy products for men with recurring prostate cancer and rising prostate specific antigen. Nutr Cancer. 60:145–154. 2008. View Article : Google Scholar : PubMed/NCBI

Hamilton-Reeves JM, Rebello SA, Thomas W, Kurzer MS and Slaton JW: Effects of soy protein isolate consumption on prostate cancer biomarkers in men with HGPIN, ASAP, and low-grade prostate cancer. Nutr Cancer. 60:7–13. 2008. View Article : Google Scholar : PubMed/NCBI

Pendleton JM, Tan WW, Anai S, Chang M, Hou W, Shiverick KT and Rosser CJ: Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer. 8:1322008. View Article : Google Scholar : PubMed/NCBI

Kumar NB, Kang L, Pow-Sang J, Xu P, Allen K, Riccardi D, Besterman-Dahan K and Krischer JP: Results of a randomized phase I dose-finding trial of several doses of isoflavones in men with localized prostate cancer: Administration prior to radical prostatectomy. J Soc Integr Oncol. 8:3–13. 2010.PubMed/NCBI

deVere White RW, Tsodikov A, Stapp EC, Soares SE, Fujii H and Hackman RM: Effects of a high dose, aglycone-rich soy extract on prostate-specific antigen and serum isoflavone concentrations in men with localized prostate cancer. Nutr Cancer. 62:1036–1043. 2010. View Article : Google Scholar : PubMed/NCBI

Kwan W, Duncan G, Van Patten C, Liu M and Lim J: A phase II trial of a soy beverage for subjects without clinical disease with rising prostate-specific antigen after radical radiation for prostate cancer. Nutr Cancer. 62:198–207. 2010. View Article : Google Scholar : PubMed/NCBI

Lazarevic B, Boezelijn G, Diep LM, Kvernrod K, Ogren O, Ramberg H, Moen A, Wessel N, Berg RE, Egge-Jacobsen W, et al: Efficacy and safety of short-term genistein intervention in patients with localized prostate cancer prior to radical prostatectomy: A randomized, placebo-controlled, double-blind Phase 2 clinical trial. Nutr Cancer. 63:889–898. 2011. View Article : Google Scholar : PubMed/NCBI

Hamilton-Reeves JM, Banerjee S, Banerjee SK, Holzbeierlein JM, Thrasher JB, Kambhampati S, Keighley J and Van Veldhuizen P: Short-term soy isoflavone intervention in patients with localized prostate cancer: A randomized, double-blind, placebo-controlled trial. PLoS One. 8:e683312013. View Article : Google Scholar : PubMed/NCBI

van Die MD, Bone KM, Emery J, Williams SG, Pirotta MV and Paller CJ: Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: A systematic review of randomised trials. BJU Int. 117 Suppl 4:S17–S34. 2016. View Article : Google Scholar

van Die MD, Bone KM, Williams SG and Pirotta MV: Soy and soy isoflavones in prostate cancer: A systematic review and meta-analysis of randomized controlled trials. BJU Int. 113:E119–E130. 2014. View Article : Google Scholar : PubMed/NCBI

Posadzki P, Lee MS, Onakpoya I, Lee HW, Ko BS and Ernst E: Dietary supplements and prostate cancer: A systematic review of double-blind, placebo-controlled randomised clinical trials. Maturitas. 75:125–130. 2013. View Article : Google Scholar : PubMed/NCBI

Zhu Y, Xu H, Li M, Gao Z, Huang J, Liu L, Huang X and Li Y: Daidzein impairs Leydig cell testosterone production and Sertoli cell function in neonatal mouse testes: An in vitro study. Mol Med Rep. 14:5325–5333. 2016. View Article : Google Scholar : PubMed/NCBI

Lehraiki A, Messiaen S, Berges R, Canivenc-Lavier MC, Auger J, Habert R and Levacher C: Antagonistic effects of gestational dietary exposure to low-dose vinclozolin and genistein on rat fetal germ cell development. Reprod Toxicol. 31:424–430. 2011. View Article : Google Scholar : PubMed/NCBI

Caceres S, Silvan G, Martinez-Fernandez L, Illera MJ, Millan P, Monsalve B, Peña L and Illera JC: The effects of isoflavones on androgens and glucocorticoids during puberty on male Wistar rats. Reprod Domest Anim. 49:611–617. 2014. View Article : Google Scholar : PubMed/NCBI

Yi MA, Son HM, Lee JS, Kwon CS, Lim JK, Yeo YK, Park YS and Kim JS: Regulation of male sex hormone levels by soy isoflavones in rats. Nutr Cancer. 42:206–210. 2002. View Article : Google Scholar : PubMed/NCBI

Weber KS, Setchell KD, Stocco DM and Lephart ED: Dietary soy-phytoestrogens decrease testosterone levels and prostate weight without altering LH, prostate 5alpha-reductase or testicular steroidogenic acute regulatory peptide levels in adult male Sprague-Dawley rats. J Endocrinol. 170:591–599. 2001. View Article : Google Scholar : PubMed/NCBI

Kumar NB, Krischer JP, Allen K, Riccardi D, Besterman-Dahan K, Salup R, Kang L, Xu P and Pow-Sang J: A Phase II randomized, placebo-controlled clinical trial of purified isoflavones in modulating steroid hormones in men diagnosed with localized prostate cancer. Nutr Cancer. 59:163–168. 2007. View Article : Google Scholar : PubMed/NCBI

Hamilton-Reeves JM, Vazquez G, Duval SJ, Phipps WR, Kurzer MS and Messina MJ: Clinical studies show no effects of soy protein or isoflavones on reproductive hormones in men: Results of a meta-analysis. Fertil Steril. 94:997–1007. 2010. View Article : Google Scholar : PubMed/NCBI

Adlercreutz H, Höckerstedt K, Bannwart C, Bloigu S, Hämäläinen E, Fotsis T and Ollus A: Effect of dietary components, including lignans and phytoestrogens, on enterohepatic circulation and liver metabolism of estrogens and on sex hormone binding globulin (SHBG). J Steroid Biochem. 27:1135–1144. 1987. View Article : Google Scholar : PubMed/NCBI

Berrino F, Bellati C, Secreto G, Camerini E, Pala V, Panico S, Allegro G and Kaaks R: Reducing bioavailable sex hormones through a comprehensive change in diet: The diet and androgens (DIANA) randomized trial. Cancer Epidemiol Biomarkers Prev. 10:25–33. 2001.PubMed/NCBI

Sawada N, Iwasaki M, Inoue M, Sasazuki S, Yamaji T, Shimazu T and Tsugane S: Japan Public Health Center-based Prospective Study Group: Plasma testosterone and sex hormone-binding globulin concentrations and the risk of prostate cancer among Japanese men: A nested case-control study. Cancer Sci. 101:2652–2657. 2010. View Article : Google Scholar : PubMed/NCBI

Tanaka M, Fujimoto K, Chihara Y, Torimoto K, Yoneda T, Tanaka N, Hirayama A, Miyanaga N, Akaza H and Hirao Y: Isoflavone supplements stimulated the production of serum equol and decreased the serum dihydrotestosterone levels in healthy male volunteers. Prostate Cancer Prostatic Dis. 12:247–252. 2009. View Article : Google Scholar : PubMed/NCBI

Bae M, Woo M, Kusuma IW, Arung ET, Yang CH and Kim YU: Inhibitory effects of isoflavonoids on rat prostate testosterone 5α-reductase. J Acupunct Meridian Stud. 5:319–322. 2012. View Article : Google Scholar : PubMed/NCBI

Hu GX, Zhao BH, Chu YH, Zhou HY, Akingbemi BT, Zheng ZQ and Ge RS: Effects of genistein and equol on human and rat testicular 3beta-hydroxysteroid dehydrogenase and 17beta-hydroxysteroid dehydrogenase 3 activities. Asian J Androl. 12:519–526. 2010. View Article : Google Scholar : PubMed/NCBI

McVey MJ, Cooke GM and Curran IH: Altered testicular microsomal steroidogenic enzyme activities in rats with lifetime exposure to soy isoflavones. J Steroid Biochem Mol Biol. 92:435–446. 2004. View Article : Google Scholar : PubMed/NCBI

Ohno S, Nakajima Y, Inoue K, Nakazawa H and Nakajin S: Genistein administration decreases serum corticosterone and testosterone levels in rats. Life Sci. 74:733–742. 2003. View Article : Google Scholar : PubMed/NCBI